naxitamab (Danyelza) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Breakthrough Therapy FDA Accelerated Approval FDA
AACT ChEMBL PubChem
Back

Drug Pricing Summary

VA FSS

$15246.3200

Drug Product Pricing

Product $/unit Ctry. List Type
Product (units) Manufacturer
naxitamab 40 mg / 10 mL (10 mL INJECTION) $15246.3200 VA FSS
  • DANYELZA (1)
    		•  Y-mAbs Therapeutics

    Note: This drug pricing data is preliminary, incomplete, and may contain errors.

    Feedback

    Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

    Report issue